Data presented at ASH 2011 evaluate a genetic marker that may help identify high-risk patients and potential therapeutic targets for cardiovascular disease prevention.
Data presented at ASH 2011 press briefing.
Data presented at ASH 2011 press briefing showcases evidence that low fitness levels and the consumption of coffee and alcohol impact blood pressure.
President of ASH and President of ASH Specialist Program Announce New Code and other Key Initiatives at Launch of 2011 Annual Scientific Meeting and Exposition in New York City.
In addition to highlighting the latest clinical research, this year’s meeting will provide insights into the pathobiology of hypertension, translational issues in hypertension and the therapy of hypertension.
In recognition of World Diabetes Day on November 14th, the Making Sense of Diabetes video contest is challenging people living with diabetes to visually reveal its impact on their lives through one of the five senses: sight, hearing, taste, touch or smell. The contest is sponsored by the Diabetes Hands Foundation, a pioneering advocacy organization in social media, and made possible through support provided by Boehringer Ingelheim Pharmaceuticals, Inc.
New paper calls for urgent clinical research and updated treatment approaches to halt the rising levels of premature death in obese children with hypertension.
New recommendations published in the Journal of Clinical Hypertension call for patient-centered management and early, aggressive treatment of hypertension in this high risk group.
Neuronetics, Inc., a privately-held medical device company and a leader in the field of neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has cleared its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system for the treatment of depression. NeuroStar TMS Therapy is specifically indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
ProStrakan Group plc (LSE: PSK) today announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.
Precision Therapeutics Inc. announced today that the ChemoFx Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.
A new survey shows that a significant percentage of oncology nurses "“ 56 percent, or 325 nurses "“ report having had to stop or delay their patients' treatment because of chemotherapy-induced nausea or vomiting "“ CINV "“ and they cite it as one of the most important factors, after fatigue, that affect cancer patients' quality of life.
The Walter Reed Army Institute of Research (WRAIR) and the U.S. Army Medical Materiel Development Activity (USAMMDA), announced today a new partnership with Sigma-Tau Pharmaceuticals, Inc. to help finalize the research and development of a new and promising treatment for severe malaria.
TCT Hot Topic Press Conferences: Interactive Q&A press briefings to be held on Wednesday, October 25 at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C
1) ZOMAXX I: Mixed results with zotarolimus-eluting stent; 2) LONG-DES II: Cypher more effective for long lesions; 3) NORDIC BIFURCATION: Optional side branch stenting as effective as mandatory stenting.
Late-breaker press conferences October 23-25 at the Transcatheter Cardiovascular Therapeutics Symposium (TCT) in Washington, DC will announce the latest findings of clinical trials of drug-eluting stents and other new heart devices, medications and procedures in interventional cardiology.
Healthcare Experts Recognize Triglycerides as an Overlooked Risk Factor for Heart Disease and Cite Need for Improved Patient Education
New data has shown that VSL#3 provides effective relief in the dietary management of serious intestinal disorders such as ulcerative colitis and pouchitis. Based on recently published research from the Mayo Clinic, an independent panel of qualified experts has determined that VSL#3 is generally recognized as safe (GRAS), under the conditions of intended use as a medical food for the dietary management of irritable bowel syndrome (IBS).
Interactive on-line media briefing on diagnosis and treatment of Age-Related Macular Degeneration (AMD), the leading cause of vision loss among Americans above the age of fifty.
A study of patients with uncontrolled hypertension found that although nearly two-thirds had high or very high cardiovascular risks and risk factors, nearly one-third of their primary care physicians did not consider that those patients required a change in any hypertension treatment they were taking.
A study presented today at the 21st Annual Meeting of the American Society of Hypertension in New York City found that female sexual dysfunction (FSD) is more prevalent in women with hypertension compared to those with normal blood pressure, and that age and duration of hypertension appear to be significant predictors of FSD.
A study of more than eight thousand adolescents indicates that, without pharmacological treatment or life-style changes, young people with prehypertension or high blood pressure appear more likely to become hypertensive young adults, and consequently be at risk for the damaging consequences of hypertension, as their lives progress.
Stevo Julius, MD, ScD, Emeritus Professor of Internal Medicine and Physiology at the University of Michigan examined the implications of the TROPHY (Trial Of Preventing Hypertension) study today in New York City in a panel discussion at the 21st Annual Scientific Meeting of the American Society of Hypertension (ASH 2006).
A study of more than five thousand African Americans found that individuals who were involved with or participated in religious activities had significantly lower blood pressure than those who were not, despite being more likely to be classified as hypertensive, having higher levels of body mass index (BMI), and lower levels of medication adherence.
Data from the largest epidemiological study of cardiovascular disease (CVD) and its risk factors in the American Indian community may indicate racial differences in the development of hypertension and that different risk factors are more predictive in men than in women.
Data from clinical studies presented today at the 21st Annual Scientific Meeting of the American Society of Hypertension (ASH 2006), show that aliskiren, the first in a new class of orally active renin inhibitors for the treatment of hypertension, provided effective blood pressure control both alone and in combination with a widely-used diuretic.
A new study presented today indicates that cognitive function is adversely affected by exaggerated blood pressure variability, or the difference between systolic and diastolic readings, in elderly patients 80 years of age and older.
The American Society of Hypertension's 21st Annual Scientific Meeting will be held in New York City, Tuesday, May 16th through Saturday, May 20th at the New York Hilton Hotel.
As part of a new educational program called Ages & Stages, a survey of more than 1,200 women with depression revealed that their views of, and experiences with, the illness varied considerably depending on their age, often leading to misunderstanding of the illness, misdiagnosis and lack of proper care.
A looming shortage of specialists, and the need for research focusing on prevention as well as treatment, are two of the most important challenges in managing an inexorable growth in the incidence of hypertension.
The Lymphoma Research Foundation is announcing the launch of a new educational initiative called LAMP (Lymphoma Awareness for Multicultural Populations), to provide underserved populations with much-needed education about lymphoma, the most common blood cancer and third most common cancer in children.
Media briefing by four nationally-recognized experts discussing the "State of the Hypertension Nation: Recent Advances & Future Trends".
Research has shown that cryoplasty, a minimally-invasive treatment that utilizes freezing-cold nitrous oxide injected into an angioplasty balloon, appears to be more effective than standard therapies in the treatment of peripheral artery disease in the lower limbs.
Treatment with statins, which have an anti-inflammatory effect and reduce C-reactive protein levels, have been shown to decrease the risk of periprocedural coronary events.
An encouraging study has shown that transplantation of bone marrow stem cells into the heart improves heart function and blood flow in heart attack patients for up to six months.
A new study has shown that plaque excision with a new device called the SilverHawk is beneficial as a primary therapy in revascularization of lower extremity peripheral arterial disease.
Results are available from the first-ever human trial of a new device that uses radiofrequency energy to close a patent foramen ovale, a flap-like opening between the upper chambers of the heart. PFO closures have been successfully performed for more than 10 years using catheters to insert permanent devices to seal a PFO.
Very promising one-year results from the first study of a new minimally invasive procedure that uses a small clip to help properly close the leaflets of the mitral valve in patients with mitral regurgitation are available.
Results from the first-in-man trial of a self-contained magnetic resonance imaging catheter designed to evaluate the composition of plaque found in the heart are available.
A just-published recommendation for an expanded definition of hypertension urges physicians to look beyond the numbers obtained from blood pressure readings, and instead, view hypertension as a progressive cardiovascular syndrome that can begin before elevated blood pressure appears.
The Cardiovascular Research Foundation will host a roundtable discussion on the critical role that nurses play in patient education, cardiovascular risk awareness and patient empowerment.
New advances and pioneering innovations changing the landscape of interventional vascular therapy & vascular medicine.
Writing group urges expansion of the definition of hypertension -- move paves the way for new avenues in disease management and research efforts.
Emerging evidence supports early detection, monitoring, and in some cases treatment for children suffering from condition.
Small study suggests drug may mimic beneficial effects of ACE inhibitors/ARB.
Study shows regular habitual physical exercise most beneficial in absence of other cardiovascular risks.
Anticipation of changes in blood pressure attributed to time of day and month of year may improve the accuracy of diagnosis and precision of treatment.
When mental stress sparks a significant rise in blood pressure, it may be a sign of other existing cardiovascular risk factors, researchers reported today.
Widely-used erectile dysfunction treatment effective in reducing aortic stiffness.
This year's program will feature the new definition and classification of hypertension, which could significantly change and improve the way physicians diagnose and treat hypertension.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right